Bills · HR 3375
IN COMMITTEE· 119TH CONGRESS
House BillHR 3375Health
Fair Prescription Drug Prices for Americans Act
INTRO MAY 13· LAST ACTION MAY 13
READING
3MIN
COSPONSORS
0
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
- Introduced only
LEGISLATIVE PROGRESS
STEP 2 / 8Introduced
In Committee
Reported
Passed House
Passed Senate
Conference
To President
Became Law
WHAT THE BILL DOES
AI-writtenThis bill addresses the often-cited issue of high prescription drug prices in the United States, which many argue are significantly higher than in other developed nations. If it becomes law, it could lead to a noticeable reduction in what Americans pay at the pharmacy, directly impacting their wallets and healthcare budgets. This could improve access to medication and reduce financial stress for millions.
However, if it doesn't pass, drug prices in the U.S. are likely to continue following current trends, which have often shown prices increasing faster than inflation. The debate around this bill highlights a fundamental tension: balancing pharmaceutical companies' ability to set prices, recoup research and development costs, and innovate, against the public's need for affordable, accessible healthcare.
KEY PROVISIONS
4AI-extractedPROVISION 01
Establishes a price cap for prescription drugs and biological products in the U.S., preventing their retail list price from exceeding the average price in Canada, France, Germany, Italy, Japan, and the United Kingdom.
This directly aims to lower drug costs for American consumers by linking them to international prices.
PROVISION 02
Requires the Secretary of Health and Human Services to annually calculate the average retail list price for each drug and biological product in the specified six foreign countries.
This sets up the mechanism for determining the maximum allowable price in the U.S.
PROVISION 03
Mandates that drug and biological product manufacturers annually submit their U.S. and international list prices to the Secretary.
This provides the necessary data for the government to enforce the price cap.
PROVISION 04
Imposes a civil monetary penalty on manufacturers who violate the price cap, calculated as 10 times the difference between the U.S. list price and the international average price, per unit sold.
This provision creates a strong financial deterrent to prevent manufacturers from overcharging.
SPONSORSHIP
1 + 0
R· New Jersey
YRS IN OFFICE
7
BILLS LED
57
ACTION TIMELINE
2 EVENTSMAY 13
Introduced in House
MAY 13
Referred to the House Committee on Energy and Commerce.
BILL INFO
TypeHouse Bill
NumberHR 3375
Congress119th
StatusIn Committee
IntroducedMay 13, 2025
Last actionMay 13, 2025
READER REACTIONS
OVERALL SENTIMENT
No reactions yet. Be the first to weigh in.
Discussion
Loading comments...
IN COMMITTEE· 119TH CONGRESS · ENERGY AND COMMERCE COMMITTEE · INTRODUCED MAY 13, 2025
House BillHR 3375Health
Fair Prescription Drug Prices for Americans Act
INTRODUCED MAY 13, 2025· LAST ACTION MAY 13, 2025
PASSAGE CHANCES
—%
READING
3 min
COSPONSORS
0
COMPLEXITY
Moderate
